At My Concierge MD, Our team of highly qualified and experienced physicians is dedicated to delivering exceptional medical care to our patients. We offer a range of services, including preventive care, urgent care, chronic disease management, and health and wellness programs.
Sermorelin, also known as sermorelin acetate, does not carry that risk, unlike HGH therapy, which carries the modest risk of raising growth hormone levels in the bloodstream, which is too high. Sermorelin was licensed by the FDA in 1997 to treat growth hormone deficiency. Growth hormone levels in the body are not raised by sermorelin. Instead, it stimulates the pituitary gland to increase low GH production to a more balanced level. Because of this, sermorelin side effects are less common than those associated with the use of HGH.
A licensed diagnostic test for growth hormone secretion is Sermorelin. Children who lack growth hormones can also be treated with it. However, in November 2002, the firm pulled items containing sermorelin off the American market.
What are the benefits of Sermorelin?
Sermorelin may be able to raise your growth hormone levels when used in conjunction with a tailored strategy that targets your lower levels. Sermorelin peptide therapy has varying positive and negative effects depending on the patient. Even while you might not encounter all of the effects listed, you can still experience others that you can discuss with your doctor.
Boosts Pituitary Hormone Production
Sermorelin peptide has been studied extensively for its capacity to stimulate the pituitary gland into producing more human growth hormone (HGH). This synthetic peptide has 29 amino acids and mimics the natural hormone growth hormone-releasing hormone (GHRH). Sermorelin has been found to increase HGH levels in the body. Because of this, Sermorelin is known as a secretagogue. It is not a cure-all for aging or growth hormone shortages and should only be administered under the supervision of a medical specialist.
Sermorelin, also known as synthetically produced GRF1-29, has the same amino acid composition as the first 29 amino acids in the natural hypothalamic GHRH1-44. However, the pharmaceutical use of hGRF1-29 has limitations due to its short half-life in plasma, which lasts only 10-20 minutes in humans. This is mainly because it is eliminated through the kidneys and undergoes enzymatic degradation at the N terminus. Different PEGylated GRF conjugates were produced, and their bioactivity was assessed in vitro and in vivo by measuring endogenous growth hormone (GH) blood levels following intravenous (i.v.) and subcutaneous injections in rats and pigs. GRF-PEG conjugates were discovered to bind and activate the human GRF receptor, but with varying potencies.